Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial
British Journal of Dermatology · 27.01.2026 · 194 (2) · 216-224
DOI: 10.1093/bjd/ljaf350 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Dermatology, online erschienen am 04.09.2025. Verfasst von Sebastian Haferkamp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Cancer Aid.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with BRAF wildtype metastatic melanoma who exhibit primary resistance to immune checkpoint inhibitors (ICIs) have a poor prognosis. Chemotherapy has been shown to induce genetic mutations, modify the tumour microenvironment and microbiome, and influence immune system activity.
Objectives
To investigate in a prospective multicentre phase II trial whether two applications of an alkylating agent (dacarbazine) can sensitize patients with metastatic melanoma who are nonresponsive to ICIs to the same checkpoint inhibitor regime.
Methods
The PROMIT trial (NCT04225390) enrolled patients with histologically confirmed BRAF wildtype metastatic melanoma who exhibited primary resistance to ICI therapy. Following radiological evidence of primary resistance to ICI (ipilimumab + nivolumab or pembrolizumab) upon the first staging after initiation, patients received two doses of dacarbazine at 850 mg m–2 intravenously on days 1 and 21. Subsequently, 1 week after application of the second dose of dacarbazine, patients were rechallenged with the same ICI therapy to which they had previously shown progressive disease.
Results
In total, 53 patients were enrolled across four German skin cancer centres. Of these patients, 38 were evaluable for efficacy, having received at least one dose of ICI re-exposure. The overall objective response rate was 18% (95% confidence interval 0.08–0.34), with 7 of 38 patients achieving a partial response. The disease control rate was 37%. Therapy was well tolerated, with treatment-related ≥ grade 3 CTCAE adverse events occurring in 10% of patients. No new safety signals were observed.
Conclusions
The study indicates that short-term chemotherapy followed by ICI rechallenge can overcome primary ICI resistance in patients with melanoma, supporting its potential as a new therapeutic option in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Regensburg, Regensburg, Germany.
- Bavarian Cancer Research Center (BZKF), Erlangen, Germany.
- Goethe University Frankfurt, University Hospital, Department of Dermatology, Frankfurt, Germany.
- Department of Dermatology, Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Uniklinikum Erlangen, Erlangen, Germany.
- Department of Dermatology, University Hospital Würzburg, Würzburg, Germany.
- Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany.
ORCID-Profile: Sebastian Haferkamp, Bastian Schilling, Carola Berking, Konstantin Drexler, Anja Gesierich, Dirk Tomsitz, Edward K Geissler, Florian Zeman, Lucie Heinzerling
Förderung
- German Cancer Aid
Zitieren
APA
Haferkamp, S., Schilling, B., Berking, C., Drexler, K., Gesierich, A., Tomsitz, D., Erdmann, M., Jakob, L., Geissler, E. K., Zeman, F., & Heinzerling, L. (2026). Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. British Journal of Dermatology, 194(2), 216-224. https://doi.org/10.1093/bjd/ljaf350
Vancouver
Haferkamp S, Schilling B, Berking C, Drexler K, Gesierich A, Tomsitz D, et al. Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. British Journal of Dermatology. 2026;194(2):216-224. doi:10.1093/bjd/ljaf350
BibTeX
@article{Haferkamp2026,
author = {Haferkamp, Sebastian and Schilling, Bastian and Berking, Carola and Drexler, Konstantin and Gesierich, Anja and Tomsitz, Dirk and Erdmann, Michael and Jakob, Lea and Geissler, Edward K and Zeman, Florian and Heinzerling, Lucie},
title = {Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial},
journal = {British Journal of Dermatology},
year = {2026},
volume = {194},
number = {2},
pages = {216--224},
doi = {10.1093/bjd/ljaf350}
}
EUVIMED